Skip to content
DraconiticResearch
Search Sources API
178,033 studies31 sourcesUpdated 39 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Serum SPP1 levels are associated with disease severity and 1-year mortality in primary Sjögren’s syndrome-associated interstitial lung disease

  • Yuting Li1
  • Shenao Zhang1
  • Xiaorui Ding2
  • Qing Wang3
  • Tong Ji2
  • Hong Yao2
  • Jinghong Dai1,2,3
  1. 1Department of Pulmonary and Critical Care Medicine, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine
  2. 2Department of Pulmonary and Critical Care Medicine, The Affiliated Drum Tower Hospital of Nanjing University Medical School
  3. 3Department of Geriatrics, Nanjing Drum Tower Hospital Clinical College of Nanjing University of Chinese Medicine
Read full textPDFDOICite

Abstract

Clinical significance of serum secreted phosphoprotein 1 (SPP1) in primary Sjögren’s syndrome-associated interstitial lung disease (pSS-ILD) remains unclear. In this study, we analyzed the GSE47460 lung tissue expression profile to validate SPP1 upregulation in ILD and performed GSEA to explore the potential mechanisms. A retrospective clinical cohort of 88 pSS-ILD patients and 40 healthy controls (HC) was established, with patients stratified into stable disease (SD, n=60) and acute exacerbation (AE, n=28). Serum SPP1 levels were measured by ELISA, and correlations with pulmonary function were analyzed. ROC curves, Kaplan-Meier survival analysis, and Cox regression models were used to evaluate its predictive value. SPP1 was upregulated in ILD lung tissues, with GSEA revealing enrichment of nucleotide metabolism in the high-expression group. Serum SPP1 levels were significantly elevated in pSS-ILD patients compared to HCs [37.69 (27.25–73.42) vs. 20.11 (15.68–23.72) ng/mL, P<0.001], and further increased in the AE group [85.90 (48.67–122.45) vs. 31.45 (25.87–42.02) ng/mL, P<0.001]. SPP1 levels correlated negatively with DLCO% predicted (r = −0.426, P<0.01, q = 0.013). The AUC for distinguishing AE was 0.891, and for predicting 1-year mortality was 0.712. Using a cut-off of 40.41 ng/mL, higher SPP1 levels were associated with worse survival (P = 0.002), and multivariate Cox regression identified SPP1 as an independent risk factor for 1-year mortality (HR = 1.016, 95% CI: 1.006–1.025, P = 0.001). Collectively, these clinical findings demonstrate that serum SPP1 levels correlate with disease severity and may serve as a predictor of poor prognosis in pSS-ILD.

Related

  1. Clinical variables and quantitative CT radiomics for mortality risk stratification after acute exacerbation of idiopathic inflammatory myopathy-associated interstitial lung disease
    Liyu He, Yanrong Chen, Jingping Zhang +6
    Frontiers in immunologyPeer-reviewedCC BYFull textImmunologyEurope PMCCrossref
  2. Serum Calprotectin as predictor of Rheumatoid Arthritis disease severity and Mortality
    S. Chebbi, D. Mongin, D. S. Courvoisier +7
    bioRxivPreprintAll rights reservedFull textImmunologybioRxiv
  3. Hippocampal/medial temporal sclerosis is associated with clinical severity, regional TDP-43, and hippocampal atrophy in Alzheimer disease
    P. Sharma, R. Devappa, S. Ramamoorthy
    bioRxivPreprintAll rights reservedFull textNeurosciencebioRxiv
  4. Large-scale plasma proteomics identifies proteins and pathways associated with incident interstitial lung disease
    Zijian Kang, Ying Zhu, Jianzheng Zhang +5
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossref
  5. Tocilizumab for acute exacerbation of rheumatic disease-associated interstitial lung disease: a real-world comparative cohort study
    Wenwen Xu, Yiyangzi Ma, Danting Zhang +11
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0ImmunologyFrontiersCrossref

Cite

BibTeXRIS
BibTeX
@article{li2026serum,
  title = {{Serum SPP1 levels are associated with disease severity and 1-year mortality in primary Sjögren’s syndrome-associated interstitial lung disease}},
  author = {Yuting Li and Shenao Zhang and Xiaorui Ding and Qing Wang and Tong Ji and Hong Yao and Jinghong Dai},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1959993},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1959993/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Serum SPP1 levels are associated with disease severity and 1-year mortality in primary Sjögren’s syndrome-associated interstitial lung disease
AU  - Yuting Li
AU  - Shenao Zhang
AU  - Xiaorui Ding
AU  - Qing Wang
AU  - Tong Ji
AU  - Hong Yao
AU  - Jinghong Dai
PY  - 2026
DA  - 2026/10/12
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1959993
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1959993/full
AB  - Clinical significance of serum secreted phosphoprotein 1 (SPP1) in primary Sjögren’s syndrome-associated interstitial lung disease (pSS-ILD) remains unclear. In this study, we analyzed the GSE47460 lung tissue expression profile to validate SPP1 upregulation in ILD and performed GSEA to explore the potential mechanisms. A retrospective clinical cohort of 88 pSS-ILD patients and 40 healthy controls (HC) was established, with patients stratified into stable disease (SD, n=60) and acute exacerbation (AE, n=28). Serum SPP1 levels were measured by ELISA, and correlations with pulmonary function were analyzed. ROC curves, Kaplan-Meier survival analysis, and Cox regression models were used to evaluate its predictive value. SPP1 was upregulated in ILD lung tissues, with GSEA revealing enrichment of nucleotide metabolism in the high-expression group. Serum SPP1 levels were significantly elevated in pSS-ILD patients compared to HCs [37.69 (27.25–73.42) vs. 20.11 (15.68–23.72) ng/mL, P<0.001], and further increased in the AE group [85.90 (48.67–122.45) vs. 31.45 (25.87–42.02) ng/mL, P<0.001]. SPP1 levels correlated negatively with DLCO% predicted (r = −0.426, P<0.01, q = 0.013). The AUC for distinguishing AE was 0.891, and for predicting 1-year mortality was 0.712. Using a cut-off of 40.41 ng/mL, higher SPP1 levels were associated with worse survival (P = 0.002), and multivariate Cox regression identified SPP1 as an independent risk factor for 1-year mortality (HR = 1.016, 95% CI: 1.006–1.025, P = 0.001). Collectively, these clinical findings demonstrate that serum SPP1 levels correlate with disease severity and may serve as a predictor of poor prognosis in pSS-ILD.
SN  - 1664-3224
ER  -